Navigation Links
OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
Date:12/5/2011

IRVINE, Calif., Dec. 5, 2011 /PRNewswire/ -- OvaGene Oncology Inc., a molecular diagnostics company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that it has completed a major Licensing and Collaboration Agreement with The Moffitt Cancer Center, the only National Cancer Institute (NCI) Comprehensive Cancer Center in Florida.  The agreement provides OvaGene with exclusive worldwide rights to develop and commercialize proprietary microRNA-based assays that predict drug response for currently used cancer treating drugs. The proprietary assays were developed and validated at the Moffitt Cancer Center under the leadership of Dr. Johnathan Lancaster, a world renowned scientist and clinician specializing in Women's Cancers.

"Ovarian cancer is a deadly disease. If we are to improve outcome for patients, it is essential that we develop tools to support biologically-informed clinical decision-making" said Johnathan Lancaster, MD, PhD, Director of Center for Women's Oncology at the Moffitt Cancer Center.  "As such, we are excited about our new partnership with OvaGene. It will enable us to accelerate our microRNA laboratory findings towards the clinic, as personalized medicine tools that may benefit patients in the near-term."

"We are delighted to partner with a molecular diagnostics company dedicated to taking important technologies from the bench to the bedside," said Haskell Adler PhD MBA, Senior Licensing Manager at the Moffitt Cancer Center.  "Because of the shared vision between our two organizations, we are optimistic this is the beginning of a long and fruitful relationship involving a number of technologies developed here at Moffitt."

The technology, licensed from The Moffitt Cancer Center, includes proprietary microRNA-based biomarkers that can be used to predict response to chemotherapy in a variety of tumor types. Initially, OvaGene intends
'/>"/>

SOURCE OvaGene Oncology Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays
2. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
3. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
4. US Oncology Pharmaceutical Distribution Service Wins National Safety Council Award
5. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
6. OncologySTAT Advisors Name Years Top Developments in Cancer Treatment and Research
7. First Coast Oncology to Offer Next Generation Proton Therapy
8. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
9. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
10. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
11. Varian Medical Systems Introducing OncoView(TM) - an Oncology Specific Image Management and Storage Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Photo-Eyewear™ ( http://www.PhotoEyewear.com ) announced ... Inc. ( http://www.PogoTec.com ) to better reflect the ... and technologies it is developing and plans to commercialize. ... PogoTec™ will provide focused resources to drive key areas ... , On-Track™ – There are well over ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Global ... Training, Inc. have announced plans to conduct Romania’s first ... 2015. Through an alliance with Miami-based Stem Cell Training, ... conduct the Adipose and Bone Marrow Stem Cell Training ... a reconstructive plastic surgery specialist practicing in Bucharest and ...
(Date:6/2/2015)... June 2, 2015 TapImmune, Inc. (OTCQB: TPIV), ... investors have reached an agreement whereby the institutional investors ... warrants to provide the Company up to $4.93M in ... S-1 registration statement. Under the restructured terms and subject ... additional warrants which could result in a larger influx ...
(Date:6/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) ... Market by Product , Test, Application & End User ... The bioburden testing market is expected to ... 2014, growing at a CAGR of 9.8% from 2014 ... microbial limit testing market is segmented into consumables and ...
Breaking Biology Technology:Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2
... ... Data presented this week at the annual meeting of the Society for ... after a stroke. In prior conferences, data from the University of ... Quincy Bioscience Quincy Bioscience is a partner in the ...
... ... Senior Vice President of Commercial Development , ... Marlborough, Mass. (Vocus) October 23, 2009 -- Massachusetts-based biofuels company ... ethanol, has welcomed Kevin F. McLaughlin and Ralph M. Lerner to the Qteros leadership ...
... , NEW YORK, Oct. 23 Pulmo BioTech ... has announced that it will ultimately receive at ... contemplated by the previously announced non-binding letter of ... respect to its Pulmonary Vascular Diagnostic Product Candidate ...
Cached Biology Technology:Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference 2Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference 3Cellulosic Biofuels Leader Qteros Adds Key Positions 2Cellulosic Biofuels Leader Qteros Adds Key Positions 3Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 2Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 3Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 4
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... Washington, D.C. (April 5, 2011) -- Sealants, like weather ... of a building, byproviding a barrier that prevents water ... out. The challenge, says research chemist Christopher White of ... Gaithersburg, Maryland, is predicting when they will fail. ...
... Spanish . Genetadi Biotech has presented to ... on Human Genetics held in Murcia - a prenatal diagnostic ... microarray technology (genomic hybridisation genetic chips) and with a diagnostic ... new device, known as Amniochip, is able to detect 150 ...
... our two closest living primate relatives, chimpanzees and bonobos, ... same genus. Now, a comparative analysis of their ... these behaviors, from the aggression more typical of chimpanzees ... is that the data appears to match what we ...
Cached Biology News:Inexpensive new instruments test building sealants under real-world conditions 2New technology capable of detection of 150 genetic syndromes from an amniocentesis 2Chimp, bonobo study sheds light on the social brain 2
... system consists of [5-Bromo-4-Chloro-3-,Indolyl Phosphate/Nitro ... single component,solution. The ready-to-use BCIP/NBT ... of alkaline phosphatase to produce ... noise. ,The System Contains: , ...
...
... is primarily used for the preparation of ... for tracing. NH2-Reactive B-Phycoerythrin, a component of ... can easily make a covalent bond with ... without any activation process. Filtration Tube included ...
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
Biology Products: